Icon

ELOXATIN (nda021492)- (50MG/VIAL,100MG/VIAL)

OXALIPLATIN SANOFI AVENTIS US
50MG/VIAL,100MG/VIAL
No No
2017-Feb-09 Expired
None None
None No
ELOXATIN is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for:  adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.  treatment of advanced colorectal cancer.
4 0 3
Total Other Developers None
Drugs with Suitability No
50MG/VIAL ** ** - - -
100MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 1
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ****** ******-****** *** *********** *** ********* ****. **. **, ******** *, *********, ******, ******* (***) ***
****** **** ***** ****** **** ************** (******) **., ***. *********** **.***-*, ****** ******, ******** ****-**** ****, ******, ****** ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.